Skip to content

BBNX BBNX Stock-Based Comp

Stock-Based Comp at other companies

Insulet logo
InsuletPODD
$21.3M+17.0%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$15.66M-38.6%
Medtronic logo
MedtronicMDT
$95M+6.7%
AdaptHealth logo
AdaptHealthAHCO
$6.53M+23.3%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$16.64M+55.9%

Other financials

Income statement

See full
Revenue$27.6M+56.6%
Gross profit$16.4M+83.2%
Operating income-$24.3M-30.2%
Net income-$21.9M+23.6%
EPS (diluted)-$0.49+47.3%

Balance sheet

See full
Cash & equivalents$30.2M-28.9%
Total debt$6.9M-0.9%
Total equity$271.2M-13.5%
Total assets$304.4M-9.9%

Cash flow

See full
Operating cash flow-$23.8M-19.3%
CapEx$1.4M+314%
Free cash flow-$25.2M-24.1%

Valuation

See full
Market cap$708.98M-8.6%
Enterprise value$685.68M
P/S6.4×

Profitability

See full
Gross margin57.2%+3.2pp
Operating margin-70.1%-6.4pp
Net margin-60.3%-17.4pp
FCF margin-55.4%-14.3pp

Returns & leverage

See full
Return on equity-22.7%
Debt / equity0.0×
Current ratio10.7×-5.2×

Where this comes from

Reported directly by BBNX in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: BBNX’s 10-Q, filed April 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about BBNX's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BBNX's stock-based comp?
BBNX (BBNX) reported stock-based comp of $5.41M in Q1 2026.
How has BBNX's stock-based comp changed year-over-year?
BBNX's stock-based comp increased by 92.8% year-over-year, from $2.8M to $5.41M.
What is the long-term trend for BBNX's stock-based comp?
Over 2 years (2023 to 2025), BBNX's stock-based comp has grown at a 70.2% compound annual growth rate (CAGR), from $5.66M to $16.38M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.